

Antonios G A Kolios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4261776/publications.pdf>

Version: 2024-02-01

53
papers

1,950
citations

304743

22
h-index

265206

42
g-index

53
all docs

53
docs citations

53
times ranked

3339
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic options for CTLA-4 insufficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 736-746.	2.9	68
2	CCR7-guided neutrophil redirection to skin-draining lymph nodes regulates cutaneous inflammation and infection. <i>Science Immunology</i> , 2022, 7, eabi9126.	11.9	14
3	Sarcoidosis - a multisystem disease.. <i>Swiss Medical Weekly</i> , 2022, 152, w30049.	1.6	1
4	Biologics in atopic disease in pregnancy: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 71-89.	5.7	41
5	Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 90-113.	5.7	24
6	Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 463-468.e3.	3.8	16
7	Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by <i>Staphylococcus aureus</i> sepsis. <i>Clinical Immunology</i> , 2021, 222, 108574.	3.2	8
8	Skin-kidney crosstalk in SLE. <i>Nature Reviews Rheumatology</i> , 2021, 17, 253-254.	8.0	7
9	Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. <i>Dermatology</i> , 2021, 237, 166-178.	2.1	17
10	New therapeutic approaches in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2021, 33, 181-189.	4.3	5
11	Interleukin-2 and regulatory T cells in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 749-766.	8.0	59
12	Recurrent Herpes Zoster Ophthalmicus in a Patient With a Novel Toll-Like Receptor 3 Variant Linked to Compromised Activation Capacity in Fibroblasts. <i>Journal of Infectious Diseases</i> , 2020, 221, 1295-1303.	4.0	13
13	Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1003-1014.e8.	0.7	25
14	Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1452-1463.	2.9	112
15	Considerations on biologics for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2764-2774.	5.7	75
16	Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study). <i>Dermatology</i> , 2020, 236, 529-539.	2.1	16
17	Use of biologics in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. <i>Allergologie Select</i> , 2020, 4, 53-68.	3.1	38
18	ALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 234-241.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2313-2318.	2.4	2
20	Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis. <i>New England Journal of Medicine</i> , 2019, 381, 1975-1977.	27.0	14
21	IL-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formation. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 267-279.e4.	2.9	65
22	Pretransplant Kinetics of Anti-HLA Antibodies in Patients on the Waiting List for Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2262-2274.	6.1	11
23	Severe combined immunodeficiency (SCID) presenting in childhood, with agammaglobulinemia, associated with novel compound heterozygous mutations in DCLRE1C. <i>Clinical Immunology</i> , 2019, 200, 16-18.	3.2	5
24	Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 432-448.	5.7	37
25	Immune Thrombocytopenia as Key Feature of a Novel ADA2 Deficiency Variant: Implication on Differential Diagnostics of ITP in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 155-157.	0.6	13
26	Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab. <i>British Journal of Dermatology</i> , 2018, 178, 551-555.	1.5	17
27	TNF α and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNF α antagonists. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 23-28.	1.3	10
28	Successful treatment of SAPHO syndrome with apremilast. <i>British Journal of Dermatology</i> , 2018, 179, 959-962.	1.5	37
29	Comparison of pyoderma gangrenosum and Martorell hypertensive ischaemic leg ulcer in a Swiss cohort. <i>British Journal of Dermatology</i> , 2018, 178, e125-e126.	1.5	17
30	Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1932-1946.	2.9	344
31	Takayasu's Arteritis with Isolated Pulmonary Artery Involvement in a Middle-Aged Asian Woman with Hepatitis B and Latent Tuberculosis Infection. <i>Respiration</i> , 2017, 93, 207-211.	2.6	3
32	Clinical Disease Patterns in a Regional Swiss Cohort of 34 Pyoderma Gangrenosum Patients. <i>Dermatology</i> , 2017, 233, 268-276.	2.1	16
33	Cutaneous <i>Corynebacterium</i> Infection Presenting with Disseminated Skin Nodules and Ulceration. <i>Case Reports in Dermatology</i> , 2017, 9, 8-12.	0.8	22
34	Worsening of Lymphopenia during Apremilast Treatment. <i>Case Reports in Dermatology</i> , 2017, 8, 319-322.	0.8	2
35	Rapid Growth of Lung Nodules due to Combined Pulmonary Vasculitis, Silicoanthracosis, and Chondrocalcinosis. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-4.	1.6	2
36	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. <i>Dermatology</i> , 2016, 232, 640-647.	2.1	32

#	ARTICLE	IF	CITATIONS
37	Identification of a novel <sc>PPAR</sc> γ 1/miR-21 axis in <sc>UV</sc>-induced skin inflammation. <i>EMBO Molecular Medicine</i> , 2016, 8, 919-936.	6.9	41
38	Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. <i>Dermatology</i> , 2016, 232, 655-663.	2.1	18
39	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. <i>Dermatology</i> , 2016, 232, 385-406.	2.1	39
40	Canakinumab in adults with steroid-refractory pyoderma gangrenosum. <i>British Journal of Dermatology</i> , 2015, 173, 1216-1223.	1.5	95
41	Detection of Small Changes in Psoriasis Intensity with PrecisePASI. <i>Dermatology</i> , 2015, 230, 314-317.	2.1	4
42	Severe Sweet's Syndrome with Elevated Cutaneous Interleukin-1 β after Azathioprine Exposure: Case Report and Review of the Literature. <i>Dermatology</i> , 2015, 230, 293-298.	2.1	32
43	Modulation of T cell responses by IL-2 and IL-2 complexes. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S54-7.	0.8	30
44	IL-1 β Drives Inflammatory Responses to Propionibacterium acnes In Vitro and In Vivo. <i>Journal of Investigative Dermatology</i> , 2014, 134, 677-685.	0.7	178
45	AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. <i>American Journal of Human Genetics</i> , 2014, 94, 790-797.	6.2	153
46	Counter-regulation of T cell effector function by differentially activated p38. <i>Journal of Experimental Medicine</i> , 2014, 211, 1257-1270.	8.5	32
47	Epidermal IL-15 acts as an endogenous antagonist of psoriasisform inflammation in mouse and man. <i>Journal of Experimental Medicine</i> , 2013, 210, 2105-2117.	8.5	55
48	Oral, Esophageal and Cutaneous Lichen Ruber Planus Controlled with Alitretinoin: Case Report and Review of the Literature. <i>Dermatology</i> , 2013, 226, 302-310.	2.1	33
49	Topical Treatment Habits in Psoriasis Patients Receiving Adalimumab. <i>Dermatology</i> , 2012, 224, 228-230.	2.1	3
50	Low-Dose Excimer 308-nm Laser for Treatment of Lichen Planopilaris. <i>Archives of Dermatology</i> , 2011, 147, 1325.	1.4	37
51	Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance Dose. <i>Case Reports in Dermatology</i> , 2011, 3, 124-129.	0.8	3
52	Spitzoid melanoma and micrometastases in two lymph node regions: a critical situation. <i>European Journal of Dermatology</i> , 2011, 21, 229-233.	0.6	2
53	Syphilitic Pharyngitis. <i>Archives of Dermatology</i> , 2010, 146, 570-2.	1.4	5